Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25Leukemia, Myeloid, Chronic-Phase 14Leukemia 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Recurrence 4Breast Neoplasms 4Blast Crisis 4Prostatic Neoplasms 3Neoplasms 3Bronchiolitis Obliterans Syndrome 3Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Advanced Breast Cancer 2Philadelphia Chromosome 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Indications Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancer 1

Interventions

Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Multiple Indications Cancer × Dasatinib × Clear all
NCT02297139 2023-05-06

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Bristol-Myers Squibb

Phase 2 Completed
17 enrolled 12 charts

Multiple Indications Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡